

APR 21 1983

License No. 29-01040-03  
Docket No. 030-08130  
Control No. 01286

Passaic General Hospital  
ATTN: James B. Makos  
Administrator  
350 Boulevard  
Passaic, New Jersey 07055

Gentlemen:

This is in reference to your application dated April 1, 1983, to renew License No. 29-01040-03. In order to continue our review, we need the following additional information:

1. a. Dose calibrator linearity tests must include the maximum activity that is assayed in the dose calibrator (i.e., the first elution from a new Tc-99m generator). If you wish to reserve some of the eluate for patient studies, you may assay the total elution, then withdraw 50 percent of the volume and assay this fraction. After volume correction, this fraction should give a dose calibrator reading that equals 50 percent of the total eluate activity, plus or minus 5 percent. You may then continue the linearity test using this fraction of the total activity. (The other half of the eluate, which need not be diluted for volume correction, may be used for patient studies.)

Please confirm that when generators are used the above procedures will be used.

- b. Please confirm that the time intervals for performance of your quarterly linearity test will conform to the times stated in Appendix D, item E, 1-6 of Regulatory Guide 10.8.
2. Please confirm that your procedures for the safe opening of radioactive packages shall include monitoring of the radiation exposure at 3 feet from and at the surface of the package with results recorded.
3. Please provide information as to the instrument to be used for counting your wipe tests from package surfaces and your weekly area wipe tests. If the instrument used is the low level survey meter stated in Appendix C, please verify that this survey meter has a thin-end window probe.
4. Please confirm that if generators are not returned to the manufacturer for disposal, that they will be held for decay as per Appendix J, Section 2, paragraph 2.

OFFICE  
8512040097 850815  
REQ1 LIC30  
29-01040-03 PDR

ML10

APR 21 1983

5. Please note that Group IV already includes iodine-131 as iodide for treatment of hyperthyroidism, therefore, it need not have been marked as an additional item on your application.

We will continue our review upon receipt of this information. Please reply in duplicate to my attention at the Region I office and refer to Mail Control No. 01286.

Sincerely,

Original Signed By  
John E. Glenn, Ph.D.

John E. Glenn, Ph.D., Chief  
Nuclear Materials Section B  
Division of Engineering and  
Technical Programs

Enclosures:

1. 10 CFR Parts 19, 20, 35
2. Form NRC-3

OFFICE	RI:DETP	RI:DETR				
SURNAME	Johansen/lp	Glenn				
DATE	4/20/83	4/21/83				